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1-INTRODUCTION: 
The Pharmaceutical industry in India is the world‘s 
third-largest in terms of volume .According to 
Department of Pharmaceuticals, Ministry of Chemicals 
and Fertilizers, the total turnover of India's 
pharmaceuticals industry between 2008 and September 
2009 was US$21.04 billion. While the domestic market 
was worth US$12.26 billion. According to Brand India 
Equity Foundation, the Indian pharmaceutical market is 
likely to grow at a compound annual growth rate 
(CAGR) of 14-17 per cent in between 2012-16 .India is 
now among the top five pharmaceutical emerging 
markets of the world. Exports of pharmaceuticals 
products from India increased from US$6.23 billion in 
2006–07 to US$8.7 billion in 2008–09 a combined 
annual growth rate of 21.25%.According to 
PricewaterhouseCoopers (PWC) in 2010, India joined 
among the league of top 10 global pharmaceuticals 
markets in terms of sales by 2020 with value reaching 
US$50 billion.  
The government started to encourage the growth of drug 
manufacturing by Indian companies in the early 1960s, 
and with the Patents Act in 1970. However, economic 
liberalization in 90s by the former Prime Minister P.V. 
Narasimha Rao and the then Finance Minister, Dr. 
Manmohan Singh enabled the industry to become what it 
is today. This patent act removed composition patents 
from food and drugs, and though it kept process patents, 
these were shortened to a period of five to seven years. 
The lack of patent protection made the Indian market 
undesirable to the multinational companies that had 
dominated the market, and while they streamed out, 
Indian companies carved a niche in both the Indian and 
world markets with their expertise in reverse-engineering 
new processes for manufacturing drugs at low costs. 
Although some of the larger companies have taken baby 
steps towards drug innovation, the industry as a whole 
has been following this business model until the present.  
India's biopharmaceutical industry clocked a 17 percent 
growth with revenues of Rs. 137 billion ($3 billion) in 
the 2009–10 financial year over the previous fiscal. Bio-
pharma was the biggest contributor generating 60 percent 
of the industry's growth at Rs. 88.29 billion, followed by 
bio-services at Rs. 26.39 billion and bio-agri at Rs. 
19.36 billion. In 2013, there were 4,655 pharmaceutical 
manufacturing plants in all of India, employing over 345 
thousand workers.  
The number of purely Indian pharma companies is fairly 
low. Indian pharma industry is mainly operated as well 
as controlled by dominant foreign companies having 
subsidiaries in India due to availability of cheap labor in 
India at lowest cost. In 2002, over 20,000 registered drug 
manufacturers in India sold $9 billion worth of 
formulations and bulk drugs. 85% of these formulations 
were sold in India while over 60% of the bulk drugs were 
exported, mostly to the United States and Russia. Most 
of the players in the market are small-to-medium 
enterprises; 250 of the largest companies control 70% of 
the Indian market. Thanks to the 1970 Patent Act, 
multinationals represent only 35% of the market, down 
from 70% thirty years ago.  
Most pharma companies operating in India, even the 
multinationals, employ Indians almost exclusively from 
the lowest ranks to high level management. Homegrown 
pharmaceuticals, like many other businesses in India, are 
often a mix of public and private enterprise. In terms of 
the global market, India currently holds a modest 1–2% 
share, but it has been growing at approximately 10% per 
year. India gained its foothold on the global scene with 
its innovatively engineered generic drugs and active 
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pharmaceutical ingredients (API), and it is now seeking 
to become a major player in outsourced clinical research 
as well as contract manufacturing and research. There are 
74 US FDA-approved manufacturing facilities in India, 
more than in any other country outside the U.S, and in 
2005, almost 20% of all Abbreviated New Drug 
Applications (ANDA) to the FDA are expected to be 
filed by Indian companies. Growth in other fields 
notwithstanding, generics is still a large part of the 
picture. London research company Global Insight 
estimates that India‘s share of the global generics market 
will have risen from 4% to 33% by 2007. The Indian 
pharmaceutical industry has become the third largest 
producer in the world and is poised to grow into an 
industry of $20 billion in 2015 from the current turnover 
of $12 billion.  
2. Pharma Marketing Process and its Challenge 
The pharmaceutical industry is the world‘s largest 
industry due to worldwide revenues of approximately 
US$2.8 trillion. Pharma industry has seen major changes 
in the recent years that place new demands on payers, 
providers and manufacturers. Customers now demand 
the same choice and convenience from pharma industry 
that they find in other segment. Indian Pharmaceutical 
Industry is poised for high consistent growth over the 
next few years, driven by a multitude of factors. Top 
Indian Companies like Ranbaxy, DRL, CIPLA and 
Dabur have already established their presence. The 
pharmaceutical industry is a knowledge driven industry 
and is heavily dependent on Research and Development 
for new products and growth. However, basic research 
(discovering new molecules) is a time consuming and 
expensive process and is thus, dominated by large global 
multinationals. Indian companies have only recently 
entered the area. The Indian pharmaceutical industry 
came into existence in 1901, when Bengal Chemical & 
Pharmaceutical Company started its maiden operation in 
Calcutta. The next few decades saw the 
pharmaceutical industry moving through several phases, 
largely in accordance with government policies. 
Commencing with repackaging and preparation of 
formulations from imported bulk drugs, the Indian 
industry has moved on to become a net foreign exchange 
earner, and has been able to underline its presence in the 
global pharmaceutical arena as one of the top 35 drug 
producers worldwide. Currently, there are more than 
2,500 registered pharmaceutical producers in India. 
There are 25,000 licensed pharmaceutical companies. Of 
the 465 bulk drugs used in India, approximately 430 are 
manufactured here. India has more drug-manufacturing 
facilities that have been approved by the U.S. Food and 
Drug Administration than any country other than the US. 
Indian generics companies supply 85% of the AIDS 
drugs that Doctors without Borders uses to treat 65,000 
patients in more than 35countries 
2.1 From organizational perspective following are the 
most prominent performance related issues: 
 a) Unethical practices adopted by some of the 
Propaganda base companies. 
 b) Low level of customer knowledge (Doctors, 
Retailers, Wholesalers). 
 c) Poor customer (both external & internal) acquisition, 
and Retention strategies 
d) Varying customer perception. 
e) The number and the quality of medical representatives 
f) Very high cost of territory development. 
g) High training costs of sales personnel. 
h) High attrition rate of the sales personnel. 
i) Busy schedule of doctors making them unable to give 
time to sales calls. 
j) Poor knowledge of medical representatives regarding 
the territory. 
k) Unknown value of revenue from each retailer in the 
territory 
l) Lack of ideal mechanism of sales forecasting at field 
sales level, resulting in  
 Huge deviations 
m) Lack of analysis on the amount of time invested on 
profitable and not-so profitable 
Customers and lack of time-share planning, for 
developing customer base for future and un-tapped 
markets. 
2.2 Patents 
The pharmaceutical industry develops, produces, and 
market drugs or pharmaceuticals licensed, for use as 
medications. Pharmaceutical companies are allowed to 
deal in generic and/or brand medications and medical 
devices. They are subject to a variety of laws and 
regulations regarding the patenting, testing and ensuring 
safety and efficacy and marketing of drugs. 
Most of today's major pharmaceutical companies were 
founded in the late 19th and early 20th centuries. Key 
discoveries of the 1920s and 1930s, such as insulin and 
penicillin, became mass-manufactured and distributed. 
Switzerland, Germany and Italy had particularly strong 
industries, with the United Kingdom, the United States, 
Belgium and the Netherlands following suit. 
Legislation was enacted to test and approve drugs and to 
require appropriate labeling. Prescription and non-
prescription drugs became legally distinguished from one 
another as the pharmaceutical industry matured. The 
industry got underway in earnest from the 1950s, due to 
the development of systematic scientific approaches, 
understanding of human biology (including DNA) and 
sophisticated manufacturing techniques. 
Numerous new drugs were developed during the 1950s 
and mass-produced and marketed through the 1960s. 
These included the first oral contraceptive, "The Pill", 
Cortisone, blood-pressure drugs and other heart 
medications. MAO inhibitors, chlorpromazine 
(Thorazine), haloperidol (Haldol) and the tranquilizers 
ushered in the age of psychiatric medication. Diazepam 
(Valium), discovered in 1960, was marketed from 1963 
and rapidly became the most prescribed drug in history, 
prior to controversy over dependency and habituation. 
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Attempts were made to increase regulation and to limit 
financial links between companies and prescribing 
physicians, including by the relatively new U.S. Food 
and Drug Administration (FDA). Such calls increased in 
the 1960s after the thalidomide tragedy came to light, in 
which the use of a new anti-emetic in pregnant women 
caused severe birth defects. In 1964, the World Medical 
Association issued its Declaration of Helsinki, which set 
standards for clinical research and demanded that 
subjects give their informed consent before enrolling in 
an experiment. Pharmaceutical companies became 
required to prove efficacy in clinical trials before 
marketing drugs. 
Cancer drugs were a feature of the 1970s. From 1978, 
India took over as the primary center of pharmaceutical 
production without patent protection.  
2.3 New Drug Approval (NDA): 
A pharma company has to undertake patent registration 
to protect its own interests, prior to launching its 
products in any country. To protect the interests of the 
consumers, it is necessary that the product be approved 
by the drug authorities in that country. Mostly the 
process for seeking approval is initiated alongside the 
patent registration process. 
2.4 WTO 
The developed countries of the world have put a 
pressure, across the world for uniformity in patent laws 
which is being implemented under WTO (World Trade 
Organization - earlier GATT i.e. General Agreement on 
Tariffs & Trade). Presently different countries have 
different Patent types and life period. WTO has decided 
upon a product patent life of 20 years in all countries. 
2.5 RESEARCH & DEVELOPMENT (R&D) 
Indian pharmaceutical industry is third largest in the 
world and is one of the most developed industries. 
Technologically strong and totally self-reliant, the 
pharmaceutical industry in India has low costs of 
production, low R&D costs, innovative scientific 
manpower, strength of national laboratories and an 
increasing balance of trade. Indian pharmaceutical 
industry today is ranked world class, in terms of 
technology, quality and range of medicines 
manufactured. From simple headache pills to 
sophisticated antibiotics and complex cardiac 
compounds, almost every type of medicine is now made 
indigenously. 
The industry today can boast of producing the entire 
range of pharmaceutical formulations, i.e. medicines 
ready for consumption by patients and about 350 bulk 
drugs, i.e., chemicals having therapeutic value and used 
for production of pharmaceutical formulations. 
The pharmaceutical industry in India is stated to be 
valued at approximately US$ 12.26 billion as per 
industry estimates. This industry is growing @ 10-11% 
per annum on compounded growth rate basis. Although 
total turnover of pharmaceutical industry is estimated at 
21.04 billion, about 65% of this revenue is from exports. 
It spends around 18 % of this revenue on research and 
development (R&D) activities. Additionally, India‘s 
clinical research industry is estimated to be a US$ 2.2 
billion with a high growth rate of 23%. Moreover, Indian 
pharmaceutical off-shoring industry is slated to become a 
US$ 2.5 billion opportunity by 2012, due to low R&D 
costs and a high-talent pool. 
Through the introduction of a system of product patents 
since 2005, Indian industry has today become a 
worldwide exporter of high quality generic drugs. India 
exports pharmaceuticals to many countries across the 
world, including the U.S., Germany, France, Russia and 
UK. The Indian Government is very proactive for 
boosting growth and investment in Indian 
pharmaceutical sector. It allows 100 per cent FDI under 
the automatic route in the drugs and pharmaceuticals 
sector. 
The DIPP data suggests that the drugs and 
pharmaceuticals sector has attracted an impressive level 
of FDI worth US$ 1,882.76 million during April 2000 to 
March 2011. Industrial licenses are not required in India 
for most of the drugs and pharmaceutical products. 
Manufacturers are free to produce any drug duly 
approved by the Drug Control Authority. 
This patent regime has led to the investment from many 
pharmaceutical multinationals in India. Now they are 
looking at India not only for its traditional strengths in 
contract manufacturing but also as a highly attractive 
location for research and development (R&D), 
particularly in the conduct of clinical trials and other 
services. Indian and foreign companies are continuing 
with patented drug launches in India and between 2005 
and 2010, the Indian Patent Office has granted 3,498 
product patents, as per a KPMG report. 
2.6 THE COMPETITION 
Indian pharma sales have traditionally been dominated 
by the acute segments. This has a seasonal flavor to it as 
living in a tropical country. Indians are at the mercy of 
changing seasons. Monsoon brings along with it viral 
infections, cough cold, TB and water borne diseases. The 
monsoon months—June to September are typically the 
strongest seasonally for the acute segment because of 
water-borne diseases while sales for the anti-infective 
segment are typically lower in winter months. In fact, 
January—March are known as 'healthy' months. 
Remarks a Sun Pharma spokesperson, "Over 75 percent 
of the Indian market is accounted for by acute therapy 
products, and this has not changed in the recent past."  
However there has been a perceptible increase in the 
revenues from the chronic ailments segment. As 
prevalence of chronic diseases increases, therapies for 
cardiovascular diseases and diabetes are expected to have 
the highest growth rates. According to ORG-IMS, in 
2007, the chronic segment outperformed the acute 
segment with growth of 21 percent as against 11 percent. 
In January 2008, the chronic segment continued to grow 
strongly at 18 percent. The increased prevalence of 
diseases caused by mosquito bites such as malaria, 
dengue and chickenguniya added to demand in 2006. 
This was reflected in the high growth rates in the pain 
and analgesic segments. The acute segment accounted 
for 72 percent of sales in India in January 2008.The level 
of competition on day to day basis is very high in Acute 
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segment however the degree of competition in not as 
much as high in Chronic therapy area. As doctor has to 
prescribe drug for a long time in chronic cases and 
patient is suppose to consume it without any change of 
brand. While in acute cases doctor is changing brands on 
day to day basis. In acute area however there is a large 
competition from local and propaganda companies. 
3. Pharmaceutical Company Business Strategies 
The days when the Indian pharmaceutical industry was 
synonymous with cheap generic drug production are 
passing. While generics continue to play a major part in 
the industry‘s success, many companies have started 
down the long road of drug discovery, novel product 
development and pharma services.  
With high-quality research, low-cost manufacturing 
facilities and educated personnel, the Indian 
pharmaceutical industry presents both a competitive 
threat and partnering opportunities.  
As a significant international industry India is the 
world‘s fourth largest producer of pharmaceuticals by 
volume, accounting for around 8.5% of global 
production. In value terms, production accounts for 
around 1.7% of the world total. The Indian 
pharmaceutical industry directly employs around 
600,000 people and is highly fragmented. While there 
are around 280 large R&D based pharmaceutical 
companies in India, including multinationals, 
government-owned and private companies, there are also 
around 6000 smaller licensed generics manufacturers, 
and although in reality only around 3500 companies are 
involved in pharmaceutical production. Most small firms 
do not have their own production facilities, but operate 
using the spare capacity of other drug manufacturers. 
 
A New Approach- 
The advent of pharmaceutical product patent recognition 
in January 2005 changed the ground rules for Indian 
companies. In the run up to the new post-patent era and 
since, the Indian industry has been evolving. R&D 
departments are moving away from reverse-engineering 
in favour of developing novel drug delivery systems and 
discovery research. It is anticipated that the experience of 
selling generics in the international market will hold 
Indian companies in good stead for selling their own 
branded products to these markets in the future. 
Focus on current and future markets 
The dynamics of the domestic Indian market have 
always encouraged Indian industry to pursue overseas 
lines of business. Expansion comes at a cost and some 
companies have had to restructure. In June 2009, 
Wockhardt divested its German business, Esparma and 
more recently, in March 2010, Orchid sold its generic 
injectable formulations business to Hospira but came out 
of the deal with a long term supply agreement for its 
APIs. 
INDIA 
India remains an important market for the vast majority 
of Indian companies. The indigenous industry supplies 
around 70% of the country‘s pharmaceuticals. The 
proportion of revenue derived from India depends largely 
on the strategy of the individual company and its 
penetration into overseas markets. For example, while 
Zydus Cadila aims to grow rapidly overseas, India 
remains its most important market, accounting for 55.8% 
of revenue in fiscal 2008/09. India is also Cipla‘s key 
market, generating almost half of the company‘s revenue 
in 2008/09, although this percentage has been declining 
in recent years as the company has increasingly targeted 
overseas markets. Other companies, such as Dr. Reddy‘s, 
are less reliant on the Indian market; in 2008/09, India 
contributed just 17% of the company‘s global revenue. 
 
INTERNATIONAL DEVELOPMENT 
The attractive opportunities offered by the loss of patent 
protection on several major products in the coming 
period, and resolution of the biosimilar regulatory issue 
in the US, has to be offset against price reduction 
pressures driven by the ongoing economic downturn and 
aggressive competition for the business that is on offer. 
USA: The largest generic market and the most sought 
after target for Indian companies involved in the generic 
business, is the US. As more companies gained the 
expertise to file for FDA approval, the number of 
ANDAs approved increased dramatically. In 2005, the 
number increased to 52 and subsequently increased year-
on-year, to reach 132 in 2008. In 2009, the total number 
of ANDA approvals was 125. In the first quarter of 2010, 
a further 20 were approved. 
UK: Over 80% of prescriptions in the mature UK market 
are written generically. The UK has always been a focus 
for Indian companies with 9 companies running 11 
manufacturing sites. Between January 2009 and January 
2010, Indian companies had more than 260 marketing 
authorizations approved by the UK‘s Medicines and 
Healthcare Regulatory Agency (MHRA) for a wide 
range of products. During this period, Ranbaxy received 
55 approvals; Dr. Reddy‘s received 54; Aurobindo 
received 39; and, Lupin received 25. 
Europe: Beyond the UK and Germany, significant 
European markets have been slow to adopt a vigorous 
generics drugs policy. However, pressure on 
governments to cut costs in the face of burgeoning drugs 
bills and economic recession, are seeing countries such 
as France, Italy and Spain exploring the increased use of 
generics. A number of Indian companies are either 
monitoring them from the sidelines or have already 
identified growth potential; Ranbaxy, for example is 
established in France, Germany, Italy and Spain.  
Brazil: Brazil is perhaps the most notable emerging 
generic market in recent years. According to the 
Brazilian generic industry association, Pró-Genéricos, 
prices of generic medicines have to be at least 35% 
cheaper than prices of original medicines but, in practice, 
they are up to 50% cheaper. In 2009, generic medicines 
represented 19.4% of the pharmacy sector by volume, 
increasing 19.0% over the previous year to 330.0 million 
units. In value terms, pharmacy sales of generic 
medicines increased by 24.0% to R$4.5 billion (US$2.2 
billion). Indian companies have been present in the 
Brazilian market for several years. In 2008, Indian 
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pharmaceutical exports to Brazil were valued at around 
US$166 million per year and made up a significant part 
of all trade between India and Latin America.  
Australia: Due to low prices of branded products, 
Australia is not yet a major market for generics. A 
number of leading drugs are due to lose patent 
protection, but price competition tends to be muted for 
off-patent drugs. The government is, however, currently 
looking at ways to boost generic consumption in an 
effort to rein in the overall drugs bill. The market is 
beginning to attract Indian companies, a number of 
which have gained approval from the Therapeutic Goods 
Administration for their manufacturing facilities and a 
range of products. 
Indian pharmaceutical companies are no strangers to 
competition. The Indian market is highly competitive 
with more than 300 organized players and branded 
promotional costs associated with every product, yet the 
industry is able to offer low-priced products and remain 
profitable in India. However, whether the Indian industry 
will be able to maintain the pace of expansion across the 
world is questionable in the current economic climate.  
The Indian Pharma Industry - looking beyond 
generics 
The Indian pharmaceutical industry has a long history of 
reverse-engineering and its ability to produce and 
distribute globally generic copies of pharmaceutical 
products is well proven. Post TRIPs, the R&D focus of 
Indian companies has shifted towards novel drug 
delivery systems or discovery research. But the global 
launch of innovative new products is still some way off, 
so what are the options for companies going forward? In-
licensing and custom manufacturing are alternative 
strategies to generics building upon its strengths in 
chemical synthesis and process engineering, the 
availability of highly-skilled labor and a low-cost 
manufacturing base, some companies have elected to 
pursue alternative business strategies. 
Piramal Healthcare has always partnered global 
innovator companies and, in addition to an extensive 
Indian generic business, is a global player in custom 
manufacturing and have a number of early stage 
development candidates. In May 2010, it was announced 
that Abbott had agreed to pay a total of US$3.7 billion 
for the domestic drug business, leaving Piramal to 
concentrate on its research, formulation and customer 
manufacturing businesses. 
Another company with a diverse portfolio of services is 
Jubilant Organosys. The company‘s main focus is its 
Pharmaceuticals and Life Sciences Products and Services 
business, which has grown significantly over the past 
few years. Jubilant is active in APIs, proprietary 
products, contract manufacturing of liquid and 
lyophilized sterile injectables, ointments, creams and 
liquids, radiopharmaceuticals, drug discovery services, 
medicinal chemistry services, clinical research services, 
generic dosage forms and healthcare. 
Biosimilars: 
The resolution of the regulatory issues surrounding 
biosimilars in the USA has removed at least one obstacle 
to the development of these products. As one of the 
leading producers of generic drugs, it is logical that 
Indian companies would see biosimilars as a natural 
follow-on business. Recent milestones in the 
development of biosimilars include: 
 Biocon signed a collaborative agreement with 
Mylan in June 2009 on the development, 
manufacturing, supply and commercialization of 
multiple, high-value generic biologic compounds for 
the global marketplace. The collaboration combines 
Biocon‘s scientific and biologics manufacturing 
with Mylan's global commercial footprint.  
 In March 2010, Ranbaxy and the San Diego, 
California-based Pfenex announced that they had 
entered into an agreement under which Ranbaxy will 
develop an undisclosed biosimilar therapeutic 
produced in the Pfenex Expression Technology 
platform, a pseudomonas-based recombinant protein 
technology.  
 In February 2009, Wockhardt announced that it had 
launched Glaritus, a recombinant long-acting 
human insulin analogue, in India. The company 
commented that it was the first company in the 
world, after the innovator, to launch this particular 
type of insulin, which works slowly for over 24 
hours. 
 The pharmaceutical industry covers a huge range of 
products and is active just about everywhere in the 
world. It is a heavily research-based industry that 
relies on new products and applications for 
continued growth. There are several business 
strategies that have enabled the pharmaceutical 
industry to flourish 
Patents: 
If a specific pharmaceutical company is the only one that 
is able to sell a drug to the public, the potential for huge 
profits is obviously increased. This is the premise behind 
the patent process for pharmaceutical drugs. Patents push 
the research and development process to keep striving 
for new and innovative medications 
 Core Model: 
The core model business strategy involves marketing 
large numbers of drugs from the acute therapy area to 
large, diversified markets. The success of this strategy is 
that it is not dependent on selling a small number of 
drugs. An acute condition appears suddenly and worsens 
fast, like a heart attack 
 Super Core Model: 
The super core model is when a pharmaceutical company 
will search out and distribute a small number of drugs in 
the chronic therapy area for prolonged and substantial 
sales. A chronic condition is one that will develop and 
worsen over an extended period of time, like many 
cancers. 
The bases of marketing strategies can be best described 
in these two models in both 
Acute and chronic segments: 
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1-Super Core Model: 
It involves the search for, and distribution of a small 
number of drugs from Chronic Therapy Area that 
achieve substantial global sales. The success of this 
model depends on achieving large returns from a small 
number of drugs in order to pay for the high cost of the 
drug discovery and development process for a large 
number of  patients. Total revenues are highly dependent 
on sales from a small number of drugs. This model 
incorporates highly specialized approach in the entire 
manner. Initially the competition seems more at entry 
level but since growth is stable and more in this area, 
every company is striving very hard to enter in this area. 
The major strategy in this model involves right focus to 
highly specialized customer by well trained team. 
2- Core Model: 
 Is a model in which a larger number of drugs from 
Acute Therapy Area are marketed to big diversified 
markets. The advantage of this model is that its success 
is not dependant on sales of a small number of drugs. 
Here presenting a large number of products and taking 
the advantage of opportunity cost is one of the important 
strategies. Other strategy includes daily reminders to 
cross the perceptual filter and get the brand name in to 
the sub-conscious state of mind . 
3- Marketing approaches of Super Core Model 
This approach deals with the hard core selling. For 
example in the same geographical location there are six 
sales executives for just one company, or different sales 
force or medical representative for the same drug in 
different settings of the environment. Finally if company 
goes for hard selling strategy, the hard work and 
aggressiveness of representatives will also increase. 
Therefore, they intend to have more frequent visits to 
clinic and encourage doctors to prescribe drugs. 
In this method medical representatives interact with 
doctors, and most of the sales executives are coming for 
a visit on a regular basis as this is the restriction put by 
doctors of meeting only once in a month that to on a fix 
time only, Using that opportunity usefulness of their 
products and push and pressurizing clinicians towards 
the use of their drugs. It means that basically, there are at 
least three representatives every day in busy clinic asking 
for a small meeting to support their product. 
Medical representative is backbone of pharma industry. 
A pharmaceutical company selects the medical 
representatives and assigns works to them. The 
representatives visit the clinic and meet doctors, noncore 
customer and stockiest as per company norms. Sales 
team or direct field teams try to influence prescription 
pattern of doctors in favour of their brands. 
Industry stockists send stocks to authorized stockiest as 
per the requirement. Retail requirement depends on 
weekly or monthly basis from authorized stockiest as per 
demand. Patients visit medical shop for buying 
medicines prescribed by a doctor and advertised in the 
media. In India for any pharmaceutical company, doctor 
is direct customer and patient is end customer. But for 
doctor customer is more important so he prescribed 
reputed companies medicine. In this supply chain model 
ultimately end-user (customer) is benefited out of this. 
To sell these products companies require more skilled 
field force to develop good marketing with their direct 
customer. Moreover Sales representative should have 
good product knowledge about their products over other 
products and convince direct customers and pull the 
demand for their products. This can be explained with 
the help of pull system given below 
 
 
4.2.1 Marketing approaches of Core Model 
In present situation companies are focusing more and 
more on the availability of products. 
For marketing of these products companies require more 
field force to remind their products on daily basis to their 
direct customers. The field force should have good 
knowledge about product schemes and offers. Also field 
force is required to have a good relation with retailers. 
Field force also required to ensure good availability of 
their products to convince doctors and PUSH their 
products. 
It has been observed that sometimes there are more than 
twenty representatives in a day those are meeting with 
their customers and requesting for same type of products. 
CORE CUSTOMER 
As per the requirement Retail chemists buy medicines on 
daily or weekly basis from authorized stockiest as per 
demand. Patients visit chemists for buying medicines 
either prescribed by a doctor or advertised in the media. 
Here patient is end customer and doctor is direct 
customer for any pharmaceutical company. But for 
doctor, customer (patient) is more important so he wants 
an effective supply chain management from prescribed 
company. And for pharmaceutical companies their 
customer that is doctor is more important that‘s why they 
emphasize more on supply chain management. Ultimately 
end customer is benefited out of this. 
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For marketing of these types of products companies require 
more and more skilled field force to develop good rapport 
with their direct customer (doctors). Moreover field force 
should have good product knowledge and USP of their 
products over other so as to convince doctors and PULL the 
demand for their products i.e. from Doctor to Retailer to 
Stockist to CFA to company. Following is the detail of pull 
system 
 
Figure 2: Pull System Working In Chronic Therapy 
Segment 
In this system, doctors are the core customers and the major 
thrust is given to build and retain these customers because 
they are pulling the demand for products hence companies 
also give main emphasis in building and retaining these 
customers. All efforts are being put for generating 
secondary sales i.e. from stockist to retailer. Ensuring of 
auto demand with limited availability and maximum 
liquidation of the products is the main characteristic of this 
approach. 
For retaining and developing customers, the companies 
normally provide gifts like sponsorship for various 
conferences like RSSDI, FOGSI, APICON, UPCON etc. 
For example Dabur having PASS (Professional Academic 
and Scientific Services) activities for promoting its chronic 
therapy range. Also it is interesting to note that since this is 
a pull system demand is being pulled in to the market so 
generally representatives calculate product orders i.e. 
primary sales from their stockist on the basis of following 
formula: Normally there are absolutely no chances of 
dumping of goods at stockiest and retailer level is yet 
reported also payment recovery of companies is also very 
good. 
3.2 Marketing approaches of Core Model 
In present scenario companies are focusing more and more 
on the availability of products so as to enjoy good image in 
their customer‘s (doctors) chamber. Many companies such 
as Glaxo, Pfizer, Dabur, FDC, Aventies, and Cipla etc. 
are known for their availability of Products. For marketing 
of these types of products companies require more and more 
field force to remind their products on daily basis to their 
direct customers (doctor). Moreover field force should have 
good knowledge of product schemes and offers. Also field 
force is required to have a good rapport with retailers. Field 
force also required to ensure good availability of their 
products to convince doctors and PUSH their products i.e. 
from  Stockist to Retailer and retailers to Doctor. It has been 
observed that sometimes there are more than fifteen or 
sixteen representatives in a day, meeting with their customer 
and requesting for same type of products. There can be 
various ways through which a business organization can 
achieve success in the market, but all these ways can be 
comprised into as above, then it can be rightly said that it 
revolves specifically around three parties or more; the 
triangular linkages or the relationship between these three 
parties (company, customers and competitors) determine the 
success and failure of business organization. The basis of 
success in any competitive context can be, at the most, 
elemental level commercial success; and commercial 
success can be derived either from a cost advantage or a 
value advantage or ideally from a combination of both. In 
other words, the organization with Competitive Advantage 
tends to be the cost leader in the industry or a seller of most 
differentiated products amongst all the players. Supply 
Chain Managers can provide considerable value to their 
companies by understanding the customers' delivery 
requirements. A very powerful tool for understanding these 
requirements is account segmentation. A company can use 
account segmentation to identify market segments which is 
well positioned to serve and then organize its product range 
and even SKU‘s and service in a superior way. The doctors 
are, in general, are, trying to hide from sales representatives, 
since there are too many and they are too pushy and there is 
too little time, and the representatives probably have noticed 
that the reluctant doctors have always less time for short 
meetings and less interest and tend to reduce the time of the 
visit. 
The relationship between clinicians and representatives has 
always been good and pharmaceutical companies have 
provided, and still provide, the major economical support 
for customers' which is continuous medical education. 
Something needs to be done to find solution to this problem 
that takes into account the needs of both pharmaceutical 
companies and their representatives on one side and 
physicians on the other, for a better professional interaction. 
In this system, doctors and retailers are the core customers 
and the major thrust is given to build and retain these 
customers. Here retailers are also core customer as most of 
the times they are substituting the products based on their 
own discretion. For retaining and developing customers, the 
companies normally provide utility gifts to remind the 
products on daily basis. 
Also it is interesting to note that since this is push system 
and products are being pushed in the market so generally 
representatives place product orders from their stockiest on 
the basis of SKUs sold and schemes. In this pumping the 
goods in the market are ensuring more and more primary 
sales i.e. from CFA to Stockiest and stockiest to retailers. 
Normally the chances of dumping of goods at stockiest and 
retailer level are reported, which makes recovery of 
payments by companies difficult. 
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Figure 3: Push System Working In Acute Therapy 
Segment 
Here the role of supply chain managers can be to provide 
considerable value to their companies by understanding the 
customers' delivery requirements. A very powerful tool for 
understanding these requirements is account segmentation. 
A company can use account segmentation to identify market 
segments Such as Acute & Chronic therapy markets, which 
is well positioned to serve and then organize its product 
range and even SKU‘s and service in a superior way. 
Companies are fighting (for customers) like never before 
and if anything is certain then it is further intensification of 
this war, and because of this companies are increasingly 
looking at Logistics, as a weapon to gain Competitive 
Advantage and it is true that Logistics has the potential to 
do so, and corporate cases associated with them are given 
Low. 
CONCLUSIONS 
Through various ways a business organization can achieve 
success in the market, but all those ways can be comprised 
into as above, we can rightly say that it revolves specifically 
around three parties or more, The relationship between these 
three parties (company, customers and competitors) 
determine the success and failure of business organization. 
From medium to long run, the domestic pharmaceutical 
market will be largely driven by the increasing prevalence 
of chronic segment. The domestic pharma industry is 
principally being driven by the chronic segment which has 
grown by 18.1% this year. Against the backdrop up- take of 
acute segments has been slow and has grown by 10.3% 
only. The basis of success in any competitive context can 
be, at elementary level commercial success; and commercial 
success can be derived from either a cost advantage or a 
value advantage or ideally from a combination of both. In 
other words, the companies with Competitive Advantage 
tends to be the cost leader in the industry or a seller of most 
differentiated products will become the market leader 
amongst all the players. At last the role of supply chain is 
very important in both the phases (in acute as well as in 
chronic).The successes of any pharmaceutical industry; 
when a company changes its focus from ―Acute‖ to 
―Chronic‖ therapy market depend on competitiveness of 
supply chain. Supply Chain Management can provide 
considerable value to their companies by understanding the 
customers' delivery requirements. A powerful tool for 
understanding these requirements is account segmentation. 
A company can use account segmentation to identify market 
segments Such as Acute & Chronic therapy market. which 
is well positioned to serve and then organize its product 
range and even SKU‘s? The company must tailor its supply 
chain offerings to meet the needs of each of the market 
segment it caters. For example, Dabur India launched its 
products which were G.P. (Acute Therapy) oriented, later it 
enter in to specialist oriented (Chronic Therapy) products 
market. 
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